Z

Zeiss

Supplies lithography optics for semiconductor manufacturing

Head of Procedures Growth - Ophthalmology

Full-Time
No salary listed
Expert
Bachelor's, Master's, MBA
Bengaluru, Karnataka, India
In Person
Sales & Account ManagementAccount Management

About the job

Requirements
  • A bachelor's degree in Life Sciences, Biomedical Engineering, Optometry, or a related field is required.
  • 12 to 16 years of experience in ophthalmic medical devices, specifically surgical platforms, intraocular lenses, or consumables; ophthalmology experience is required.
  • Direct operating-theatre-level clinical application experience in phaco and ideally vitreoretinal surgery, including personal clinical support of cataract and/or retinal surgical cases, is required.
  • A proven track record in consumable revenue management, including ownership of consumable attach-rate targets, negotiation of consumable contracts with hospital procurement, and management of consumable recovery programs with documented outcomes, is required.
  • Experience building and leading clinical specialist teams, with a minimum of 6 to 8 specialists and evidence of team development, retention outcomes, and capability-building programs, is required.
  • Experience designing and delivering surgical education programs, such as wet labs, fellowship programs, or structured clinical training, is required.
  • Prior experience managing platform utilization, diagnosing underutilization and root causes, and executing improvement programs with measurable consumable revenue outcomes is required.
Responsibilities
  • Own surgical procedure adoption across phaco, vitreoretinal, and refractive segments by driving platform utilization, clinical workflow integration, and surgeon preference through operating-theatre clinical presence and structured engagement programs.
  • Own consumable revenue as a primary profit-and-loss accountability, with targets, contract architecture, and recovery programs.
  • Build and lead the surgical sales, application specialist, and consumable specialist teams to convert equipment placements into long-term procedure partnerships.
  • Connect clinical relationships, operating-theatre visits, and education programs to defined commercial objectives and tracked outcomes.
  • Own consumable revenue as a standalone profit-and-loss line and move it toward the targeted share of surgical segment revenue over 36 months.
  • Complete an installed-base audit within the first 60 days, mapping surgical platforms to consumable attachment status, current consumable brand, and annualized account revenue.
  • Design and negotiate 12-to-24-month consumable commitment agreements tied to service agreements or equipment arrangements.
  • Coordinate with the Head of Key Accounts and Regional Sales Head to activate consumable conversion plans within 60 days of each equipment placement.
  • Track consumable attachment by account, platform, and region, identify declining rates, and implement clinical or commercial recovery actions.
  • Report monthly to the SBU head on consumable revenue versus target, attachment trends, recovery programs, and contracted annuity pipeline.
  • Own phaco and DORC Vitro platform utilization by account, benchmark it, identify underutilization, and design clinical improvement programs.
  • Lead the Surgical Sales and Clinical Application Specialist team, deploying specialists to priority accounts and evaluating them on utilization improvement and consumable attachment.
  • Develop and execute surgeon-level phaco engagement programs, including technique optimization clinics, outcomes-data sharing, consumable quality argumentation, and case support.
  • Drive vitreoretinal platform adoption and consumable penetration among the top 30 vitreoretinal surgeons in India.
  • Coordinate ZEISS Cataract Suite adoption in anchor accounts and own clinical workflow integration from IOL Master biometry through CALLISTO surgical planning to AT IOL implantation.
  • Coordinate phaco platform and intraocular lens relationships in shared accounts with the Head of IOL Business.
  • Own VisuMax SMILE procedure-volume growth through procedure support, outcomes data, and patient-pathway optimization.
  • Drive SMILE adoption through procedure-support programs, India-specific outcomes data, comparative clinical evidence, and patient-conversion toolkit development.
  • Manage and develop refractive practice development consultants, focusing the team on priority surgeons.
  • Own premium workflow installations across the country.
  • Deliver pre-sales technical and clinical consultation, including product demonstrations aligned to clinical workflows and patient outcomes, to support successful deal closures.
  • Engage customers in value-based technical and clinical discussions to identify pain points and deliver tailored solutions that support premiumization and workflow sales.
  • Own the surgical education component of ZEISS Academy India, including wet labs, simulation programs, structured phaco and vitreoretinal curricula, and hands-on training.
  • Design and launch the ZEISS Surgical Fellowship Program, targeting a first-year cohort of 6 to 8 phaco and vitreoretinal surgeon fellows.
  • Coordinate the ZEISS Academy India calendar with the Head of Strategic Marketing and Professional Education, owning surgical clinical content and quality.
  • Attend weekly SBU commercial reviews and present surgical and consumables performance, utilization trends, attachment progress, recovery program status, and clinical activation updates.
  • Log every clinical activation in CRM within 24 hours and hand it off to the relevant commercial head within 48 hours with full context and commercial readiness information.
  • Respond to commercial blocker requests within five working days by deploying operating-theatre specialist support, clinical evidence packages, or personal clinical engagement.
  • Ensure clinical specialists, practice development consultants, and premium workflow specialists comply with ZEISS policies, MCI guidelines, healthcare regulations, and ethical standards.
  • Maintain accurate records of clinical visits, surgical support cases, fellowship programs, and consumable contract negotiations.
  • Provide structured monthly reporting to the SBU head covering consumable revenue, attachment by account and platform, recovery progress, utilization trends, specialist team performance, and education program outcomes.
  • Manage the procedure growth and consumables budget, track each program's investment against commercial return, and reallocate funds from low-return to high-return activities.
Desired Qualifications
  • An MBA or postgraduate qualification in Business or Healthcare Management is preferred.
  • Ideally, direct operating-theatre clinical application experience in vitreoretinal surgery.

About the company

Zeiss SMT designs and makes high-precision optical systems for semiconductor manufacturing, including lithography optics, photomask solutions, and process-control components. Its products are used in lithography equipment to project circuit patterns onto silicon wafers, with responsibilities spanning advanced optics, mask technology, and monitoring tools that ensure precise, repeatable imaging.

Company Size

1,001-5,000

Company Stage

Growth Equity (Non-Venture Capital)

Total Funding

$1.1B

Headquarters

Oberkochen, Germany

Founded

2001

Get referred to Zeiss

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • First-half 2025/26 revenue reached €5.841 billion, with EBIT rising to €955 million.
  • ZEISS CLINIC 360 won FDA 510(k) clearance on August 19, 2026.
  • EURETINA 2026 launches expanded retina imaging, cataract systems, and DORC brand integration.

What critics are saying

  • ZEISS Meditec plans up to 1,000 cuts by 2029, signaling margin pressure.
  • Göttingen workers entered mediation in February 2026 after Zeiss targeted roughly 140 jobs.
  • ASML scanner timing controls ZEISS SMT revenue; any slip delays optics demand immediately.

What makes Zeiss unique

  • ZEISS supplies ASML's exclusive EUV optics, anchoring High-NA lithography through 2030.
  • ZEISS Medical Technology bundles imaging, software, and surgery across one ophthalmic workflow stack.
  • ZEISS CLINIC 360 and Collaborative Care tie devices, cloud analytics, and referrals together.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Paid Vacation
  • Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Associated Press
Oct 12th, 2026
ZEISS launches NLX X-ray inspection and DUNE wafer warpage correction for advanced chip packaging

ZEISS Semiconductor Manufacturing Technology (SMT) has launched two systems for advanced chip packaging: ZEISS NLX and ZEISS DUNE. The company announced them in San Francisco on October 12, 2026, as chips grow more complex. ZEISS NLX inspects the inside of chip packages without damaging them. It helps manufacturers spot defects in connections between stacked dies early, and it handles 300-millimetre wafers in both process development and high-volume production. ZEISS DUNE measures the topography of a wafer and corrects wafer bow individually. This helps avoid yield losses in downstream processing and prepares bonding processes. ZEISS SMT is showing the systems at SEMICON West, alongside its photomask tools. The company is also marking 100 years of business in the US in 2026.

PR Newswire
Sep 24th, 2026
ZEISS unveils retinal imaging and surgical innovations at EURETINA 2026

ZEISS Medical Technology has announced expansions to its ZEISS Retina Workflow at the EURETINA 2026 congress in Vienna. The company introduced the ZEISS ALTA DUO 300, combining OCT and fundus imaging in a single device for streamlined retinal diagnostics. ZEISS also unveiled the HMDmd CR3, a head-mounted 3D display that connects with the ZEISS ARTEVO 850 surgical microscope. The company reported that its DORC ILM-BLUE and DORC MEMBRANEBLUE-DUAL vitreoretinal surgical dyes reached a 3 million milestone. Additionally, ZEISS announced that the DORC brand will be consolidated under the ZEISS brand name, unifying the company's ophthalmic offerings. The DORC TDC VELOCE cutter continues to show improvements in 27G vitrectomy procedures, with clinical data suggesting up to 41% shorter core vitrectomy times.

PR Newswire
Sep 17th, 2026
ZEISS expands retinal imaging portfolio with new ALTA DUO 300 multimodal OCT device

ZEISS Medical Technology has expanded its retinal imaging portfolio with the launch of ZEISS ALTA DUO 300, a fully automated, compact multimodal imaging solution. The device combines optical coherence tomography (OCT) and fundus photography in a single unit, designed to provide efficient retinal assessment for eye care practices. The ALTA DUO 300 features four key diagnostic technologies: automated structural OCT with reference database and reporting, true colour fundus camera, AI-enhanced OCT-Angiography, and full chamber depth anterior OCT scanning. The device aims to integrate retinal imaging into everyday patient care through simplified workflows. The product will be showcased at the European Society of Retina Specialists congress in Vienna from 1-4 October and will be available in select markets later in 2026.

Yahoo Finance
Aug 27th, 2026
ZEISS launches DORC EVA NEXUS cataract system at ESCRS in London

ZEISS Medical Technology has launched a cataract-only configuration of its DORC EVA NEXUS ophthalmic surgical system. The system features a cataract grade selection with up to four programmable presets, allowing surgeons to optimise phaco, aspiration, and irrigation settings for each surgical step. The solution includes VacuFlow VTi pump, SMART IOP, and EVA EQUIPHACO technologies, designed to provide streamlined performance, stability, and control during procedures. It integrates with the ZEISS Cataract Workflow portfolio. The system debuted at the European Society of Cataract and Refractive Surgeons congress in London. It will become available in select European countries from September 2026, with global rollout pending regulatory approvals. The technology expands ZEISS's existing EVA NEXUS platform, which previously focused on retina workflows.

PR Newswire
Aug 19th, 2026
ZEISS CLINIC 360 receives FDA clearance for cloud-based ophthalmic data management software

ZEISS Medical Technology announced FDA 510(k) clearance for ZEISS CLINIC 360, a cloud-based software solution that aggregates ophthalmic clinical data and provides advanced analytics. The browser-based platform combines diagnostic and medical data into a comprehensive patient view, helping clinicians evaluate disease progression and support treatment decisions. The solution integrates data from DICOM-enabled diagnostic devices, including ZEISS's CIRRUS, CLARUS and HFA systems, as well as third-party devices. It features disease-based summaries, interactive analysis tools, and collaboration capabilities through ZEISS Collaborative Care. ZEISS CLINIC 360 will be available in the US in early autumn 2026 on a subscription basis with low upfront costs. The platform complements ZEISS FORUM, the company's on-premise data management system, giving providers flexibility in choosing their preferred infrastructure approach.